The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin
| Autor: | Kurt Boman, Niklas Höglund, Jonas Andersson, Per Tornvall, Henrik Almroth, Anders Englund, Steen M. Jensen, Mårten Rosenqvist |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Atorvastatin medicine.medical_treatment Electric Countershock Cardioversion Double-Blind Method Predictive Value of Tests Recurrence Internal medicine Atrial Fibrillation medicine Humans Pyrroles In patient Prospective Studies cardiovascular diseases Aged biology business.industry C-reactive protein Atrial fibrillation Middle Aged medicine.disease Predictive value C-Reactive Protein Treatment Outcome Heptanoic Acids Cardiology biology.protein Female Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Biomarkers Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Cardiology. 167:2088-2091 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2012.05.071 |
| Popis: | The aim of this study was to investigate whether high-sensitivity C-reactive protein (hsCRP) levels prior to cardioversion (CV) predict recurrence of atrial fibrillation (AF) in patients randomized to treatment with either atorvastatin or placebo 30 and 180 days after CV.This was a prespecified substudy of 128 patients with persistent AF randomized to treatment with atorvastatin 80 mg/day or placebo, initiated 14 days before CV, and continued 30 days after CV. HsCRP levels were measured at randomization, at the time of CV, and 2 days and 30 days after CV.In univariate analysis of those who were in sinus rhythm 2h after CV, hsCRP did not significantly (odds ratio [OR] 1.11, 95% confidence interval [CI] 0.99-1.25) predict recurrence of AF at 30 days. However, after adjusting for treatment with atorvastatin, hsCRP predicted the recurrence of AF (OR 1.14, 95% CI 1.01-1.27). In a multivariate logistic regression analysis with gender, age, body mass index (BMI), smoking, cholesterol, and treatment with atorvastatin as covariates, the association was still significant (OR 1.14, 95% CI 1.01-1.29). Six months after CV, hsCRP at randomization predicted recurrence of AF in both univariate analysis (OR 1.30, 95% CI 1.06-1.60) and in multivariate logistic regression analysis (OR 1.33, 95% CI 1.06-1.67).HsCRP was associated with AF recurrence one and six months after successful CV of persistent AF. However, the association at one month was significant only after adjusting for atorvastatin treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect